Screening for Atrial Fibrillation in Sub-Saharan Africa: A Health Economic Evaluation to Assess the Feasibility in Nigeria
References
- World Health Organization. Global status report on non-communicable disease; 2014.
- Di Cesare M, Khang Y, Asaria P, et al. Inequalities in non-communicable diseases and effective responses. Lancet. 2013; 381(9866): 585–597. DOI: 10.1016/S0140-6736(12)61851-0
- World Health Organization. Global health estimates 2014 summary table; 2014.
- Institute for Health Metrics and Evaluation. Global Burden of Disease (GDB) Compare; 2016. Retrieved from
https://vizhub.healthdata.org/gbd-compare/ . (accessed 07/03, 2019). - World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. 2018.
- Moran A, Forouzanfar M, Sampson U, et al. The epidemiology of cardiovascular diseases in sub-Saharan Africa: The Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Prog Cardiovasc Dis. 2013; 56(3): 234–239. DOI: 10.1016/j.pcad.2013.09.019
- World Health Organization, World Economic Forum. From burden to ‘best buys’: Reducing the economic impact of NCDs in low- and middle-income countries; 2011.
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 7 October 2016; 37(38): 2893–2962.
- Jacobs MS, van Hulst M, Adeoye AM, et al. Atrial Fibrillation in Africa – An Underreported and Unrecognized Risk Factor for Stroke: A Systematic Review. Global Heart. 2019; 14: 269–279. DOI: 10.1016/j.gheart.2019.04.003
- Murphy A, Banerjee A, Breithardt G, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Glob Heart. December 2017; 12(4): 273–284. DOI: 10.1016/j.gheart.2017.01.015
- Tieleman RG, Plantinga Y, Rinkes D, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace. 2014; 16: 1291–5. DOI: 10.1093/europace/euu057
- Taggar JS, Coleman T, Leiws S, Heneghan C, Jones M. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. European Journal of Preventive Cardiology. 2016: 23; 1330–1338. DOI: 10.1177/2047487315611347
- Healey JS, Connoly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. New Eng J Med. 2012; 366: 120–129. DOI: 10.1056/NEJMoa1105575
- Potpara TS, Polovina MM, Marinkovic JM, Lip GY. Comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013; 168: 4744–4749. DOI: 10.1016/j.ijcard.2013.07.234
- Flaker GC, Belwe K, Beckamn K, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149: 657–663. DOI: 10.1016/j.ahj.2004.06.032
- De Vos CB, Breithardt G, Camm J, et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. Am Heart J. 2012; 163: 887–93. DOI: 10.1016/j.ahj.2012.02.015
- Glotzer TV, Daoud EG, Wyse G, et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. Circulation: Arrhytmia and Electrophysiology. 2009; 2: 474–480. DOI: 10.1161/CIRCEP.109.849638
- Birabi B, Oke K, Dienye P, Okafur, OC. Cost Burden of Post Stroke Condition in Nigeria: A Pilot Study. Global Journal of Health Science. 2011; 4: 17–22. DOI: 10.5539/gjhs.v4n6p17
- Temu T, Lane K, Shen C, et al. Clinical characteristics and 12-month outcomes of patients with valvular and nonvalvular atrial fibrillation in Kenya. PLoS ONE. 2017; 12(9):
e0185204 . DOI: 10.1371/journal.pone.0185204 - Alkali N, Bwala S, Akano A. Stroke risk factors, subtypes, and 30-day case fatality in Abuja, Nigeria. Nigerian Medical Journal. 2013; 54(2): 129–135. DOI: 10.4103/0300-1652.110051
- Hart R, Benavente O, McBride R, Aguilar M. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med. 1999; 131(7): 492–501. DOI: 10.7326/0003-4819-131-7-199910050-00003
- Hart R, Pearce L, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857–867. DOI: 10.7326/0003-4819-146-12-200706190-00007
- National Bureau of Statistics. Demographics of Nigeria. 2018. Retrieved from
https://www.nigerianstat.gov.ng . (accessed 11/10, 2019). - Owolabi M. Impact of stroke on health-related quality of life in diverse cultures: The Berlin-Ibadan multicenter international study. Health Qual Life Outcomes. 2011; 9: 81. DOI: 10.1186/1477-7525-9-81
- Wang K, Li H, Kwong WJ, et al. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017; 6:
e006703 . DOI: 10.1161/JAHA.117.006703 - Sullivan P, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006; 26(4): 410–20. DOI: 10.1177/0272989X06290495
- Baeten S, van Exel N, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services – a non-randomized controlled cluster-trial based life table approach. Cost effectiveness and resource allocation. 2010; 8(1): 21. DOI: 10.1186/1478-7547-8-21
- Jacobs M, Kaasenbrood F, Postma M, van Hulst M, Tieleman R. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2018; 20(1): 12–18.
- World Health Organization. World Health Organization CHOosing Interventions that are Cost-Effective (CHOICE); 2014. Retrieved from
www.who.int/choice/cost-effectiveness/en . (accessed 11/19, 2019). - Bergh M, Marais C, Miller-Jansön H, Salie F, Stand M. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. S Afr Med J. 2013; 103(4): 241–245. DOI: 10.7196/SAMJ.6471
- World Bank. GDP per capita Nigeria 2019 (current US$). Retrieved from
www.data.worldbank.org . (accessed 05/23 2021). - Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. The Lancet. 2014; 383(955): 962. DOI: 10.1016/S0140-6736(13)62343-0
- Svennberg E, Engdahl J, Al-Khalili F, et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 23 2015; 131: 2176–2184. DOI: 10.1161/CIRCULATIONAHA.114.014343
- Li K, White F, Tipoe T, et al. The Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review. JMIR Mhealth Uhealth. 2019; 7(2):
e11606 . DOI: 10.2196/11606 - Semakula JR, Mouton JP, Jorgensen A, et al. A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS One. 29 2020; 15(1):
e0227458 . DOI: 10.1371/journal.pone.0227458 - Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010; 376(9745): 975–983. DOI: 10.1016/S0140-6736(10)61194-4
- Potpara TS, Polovina MM, Marinkovic JM, Lip GY. Comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013; 168: 4744–4749. DOI: 10.1016/j.ijcard.2013.07.234
- Flaker GC, Belwe K, Beckamn K, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149: 657–663. DOI: 10.1016/j.ahj.2004.06.032
- World Health Organization. Model List of Essential Medicines, 21st List. 2019(21).
- World Health Organization. Exploring the expansion of the Medicines Patent Pool’s mandate to patented essential medicines. Chapter 5 – Patented medicines that have clinical benefits but did not meet the EML Expert Review committee’s comparative cost-effectiveness criterion: Case study on novel oral anticoagulants; 2018.
- Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet. 2016; 387: 61–69. DOI: 10.1016/S0140-6736(15)00469-9
DOI: https://doi.org/10.5334/gh.893 | Journal eISSN: 2211-8179
Language: English
Submitted on: Aug 1, 2020
Accepted on: Nov 5, 2021
Published on: Dec 3, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2021 M. S. Jacobs, A. M. Adeoye, M. O. Owolabi, R. G. Tieleman, M. J. Postma, M. Van Hulst, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.